Anti-angiogenic treatment in breast cancer: Facts, successes, failures and future perspectives

详细信息    查看全文

• 作者：Kim C. Aalders^a ; ^{kim.aalders@eortc.be} ; Konstantinos Tryfonidis^a ; Elżbieta Senkus^b ; Fatima Cardoso^c ; ^{fatimacardoso@fundacaochampalimaud.pt}
• 关键词：Angiogenesis ; Breast cancer ; Bevacizumab ; VEGF ; Sorafenib ; Sunitinib ; Ramucirumab
• 刊名：Cancer Treatment Reviews
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：53
• 期：Complete
• 页码：98-110
• 全文大小：505 K
• 卷排序：53

文摘

Angiogenesis is a crucial requisite in the development of tumors. So far, anti-angiogenics have not displayed clinically significant benefit in any setting. Anti-angiogenic agents come with high costs and increased toxicity. Efforts should continue to identify predictive biomarkers for anti-angiogenic treatment.